Page 41 - Read Online

Olivera et al. Cancer Drug Resist 2019;2:53-68 I http://dx.doi.org/10.20517/cdr.2018.25 Page 63

Table 2. Summary of SNP-drug relevant associations according to PharmGKB and drug labels
Reference Risk CA Level: Drug
Drug Gene SNP Implications
Genotype Genotype D, E, T, Pk label
Azathioprine ITPA rs7270101 AA AC, CC 2B: T T Moderate risk of toxicity
Capecitabine UMPS rs1801019 GG, CG CC 2B: T A Moderate risk of toxicity
Carboplatin ERCC1 rs11615 GG AA, AG 2B: E, T I Moderate risk of inefficacy
and toxicity
ERCC1 rs3212986 AA AC, CC 2B: T Moderate risk of toxicity
GSTP1 rs1695 GG AA, AG 2A: T Moderate risk of toxicity
MTHFR rs1801133 AA AG, GG 2A: E Moderate risk of inefficacy
NQO1 rs1800566 GG AA, AG 2A: E Moderate risk of inefficacy
XRCC1 rs25487 CC CT, TT 2B: E Moderate risk of inefficacy
Cyclophosphamide GSTP1 rs1695 AA, AG GG 2A: E, T I Moderate risk of inefficacy
and toxicity
SOD2 rs4880 AA AG, GG 2B: E Moderate risk of inefficacy
TP53 rs1042522 CC CG, GG 2B: E, T Moderate risk of inefficacy
and toxicity
Cisplatin ERCC1 rs11615 GG AA, AG 2B: E, T I Moderate risk of inefficacy
and toxicity
ERCC1 rs3212986 AA AC, CC 2B: T Moderate risk of toxicity
GSTP1 rs1695 AA AG,GG 2B: T Moderate risk of toxicity
NQO1 rs1800566 GG AA, AG 2A: E Moderate risk of inefficacy
TP53 rs1042522 CC CG, GG 2B: E, T Moderate risk of inefficacy
and toxicity
XPC rs2228001 TT GT, GG 1B: T High risk of toxicity
XRCC1 rs25487 CC CT, TT 2B: E Moderate risk of inefficacy
Doxorubicin NQO1 rs1800566 GG AA, AG 2A: E I Moderate risk of inefficacy
Etoposide DYNC2H1 rs716274 AA AG, GG 2B: T I Moderate risk of toxicity
Fentanyl,Metadone, ABCB1 rs1045642 AA, AG GG 2B: D, E * Moderate risk of inefficacy.
Morphine,Opioids, Consider dose increase
Oxycodone,
Tramadol
Fluorouracil GSTP1 rs1695 AG, GG AA 2A: E A Moderate risk of inefficacy
TP53 rs1042522 CC CG, GG 2B: E, T Moderate risk of inefficacy
and toxicity
UMPS rs1801019 GG, CG CC 2B: T Moderate risk of toxicity
Irinotecan C8ORF34 rs1517114 GG CG, CC 2B: T A Moderate risk of toxicity
SEMA3C rs7779029 TT CT, CC 2B: T Moderate risk of toxicity
UGT1A1 rs4148323 GG GA, AA 2A Moderate risk of toxicity
Methotrexate ABCB1 rs1045642 GG AG, AA 2A: T I Moderate risk of toxicity
ATIC rs4673993 CC, TC TT 2B: E Moderate risk of inefficacy
MTHFR rs1801133 GG AA, AG 2A: D, E, Consider dose reduction
T
MTRR rs1801394 AA AG, GG 2B: T Moderate risk of toxicity
SLCO1B1 rs11045879 CC CT, TT 2A: T Moderate risk of toxicity
Ondansetron ABCB1 rs1045642 AA AG, GG 2A: E I Moderate risk of inefficacy
Oxaliplatin ERCC1 rs11615 GG AA, AG 2B: E, T I Moderate risk of inefficacy
and toxicity
ERCC1 rs3212986 AA AC, CC 2B: T Moderate risk of toxicity
GSTP1 rs1695 GG AA, AG 2A: T Moderate risk of toxicity
NQO1 rs1800566 GG AA, AG 2A: E Moderate risk of inefficacy
XRCC1 rs25487 CC CT, TT 2B: E Moderate risk of inefficacy
Paclitaxel TP53 rs1042522 CC CG, GG 2B: E, T I Moderate risk of inefficacy
and toxicity
Rituximab FCGR3A rs396991 CC, AC AA 2B: E T Moderate risk of inefficacy
Tamoxifen CYP2D6 rs3892097 CC, CT TT 2A: E T Moderate risk of inefficacy
CYP2D6 rs3892097 TT CT, CC 2A: T Moderate risk of toxicity
Tegafur DPYD rs67376798 TT AA, AT 1A: T, Pk I High risk of toxicity